EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2019 to Jul 2024
EDAP TMS Appoints Sigmacon (UK) Ltd as Exclusive U.K.
Ablatherm(R)-HIFU Distributor
LYON, France, June 10 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP),
is pleased to announce a distribution agreement with Sigmacon UK Ltd, giving
the company exclusive rights to promote and market Ablatherm- HIFU in the U.K.
Sigmacon (UK) Ltd has more than 25 years of experience marketing a wide range
of therapeutic devices to the urological community in the U.K. The company has
extensive experience in organizing workshops and seminars promoting the
utilization of new technologies to enhance patient outcomes and grow clinical
business for physicians. Sigmacon's history of success includes technologies
such as lasers and radiofrequency devices.
Due to the exclusive partnership with Sigmacon, EDAP will be able to reach the
majority of British clinics and hospitals where urology procedures are
performed, significantly expanding the patient population which can be served
by Ablatherm-HIFU treatment for localized prostate cancer. Based on the recent
guidance from the National Institute for Clinical Excellence (NICE) supporting
the use of HIFU for the treatment of prostate cancer, Sigmacon will be actively
introducing the Ablatherm-HIFU device to the U.K. market and adding new
treatment sites. EDAP has been providing Ablatherm-HIFU treatment to British
patients from its pilot installation in Stockport for more than a year with
great success.
Hugues de Bantel, CEO of EDAP, commented: "We are excited to expand our
presence in the U.K. and confident Sigmacon is the right partner to bring
Ablatherm-HIFU technology to this market. The company has a long history in
medical devices, including winning approvals and reimbursement in the U.K. for
dedicated products. The company also has the reach and credibility within a
large medical market to increase Ablatherm-HIFU recognition, a key part of our
strategy in expanding the utilization of this innovative and highly successful
technology."
More than 27,000 men in the U.K. are diagnosed with prostate cancer every year,
and 10,000 die from the disease. Ablatherm(R)-HIFU offers an alternative
therapeutic option for patients with localized prostate cancer, particularly
for patients who are not candidates for surgery or those for whom radiotherapy
treatment has failed. In contrast to other treatment methods, Ablatherm-HIFU
requires only a short period of hospitalization and has low complication and
side-effect rates. Unlike radiation, HIFU treatment can also be safely
repeated if necessary.
David Levey, Director of Sigmacon, added, "Sigmacon has always been at the
cutting edge of medical technology. We are constantly in contact with our
customers to ensure they are fully satisfied with our innovative products
dedicated to enhance the quality of treatment available to patients. Through
our partnership with EDAP, we will work to support the business model necessary
for our customer clinics to successfully incorporate the new Ablatherm-HIFU
treatment into the daily practice. We are very excited to begin moving
Ablatherm-HIFU technology for the treatment of localized prostate cancer into
the U.K. market, while offering the patient better quality of life."
Hugues de Bantel concluded: "EDAP continues to build on its already strong
presence in key European markets, including the U.K. We are working to earn
appropriate reimbursement approvals and further the acceptance and awareness of
Ablatherm-HIFU as a preferred treatment for prostate cancer, especially in
cases where the patient's health may make traditional treatments less favorable
or in cases where the patient wishes to avoid the many side effects associated
with surgery and radiation. Ablatherm-HIFU is a safe, proven treatment method
coupled with unique business models for the clinical setting which allow for
flexible installation as a permanent or mobile treatment option."
Sigmacon will be present at the British Association of Urology Surgeons
(B.A.U.S.) meeting to be held in Glasgow, Scotland, from June 27 to July 1,
2005. An Ablatherm-HIFU unit will be on display at booth #87. Urologists are
invited to visit the Sigmacon booth to meet HIFU users and discuss the
potential of the Ablatherm-HIFU technology in the clinical setting and its
availability in the U.K.
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically
proven choice for High Intensity Focused Ultrasound (HIFU) treatment of
localized prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects. The
company is also developing this technology for the treatment of certain other
types of tumors. EDAP TMS S.A. also produces and commercializes medical
equipment for treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL).
For more information on the Company, contact the Investor Relations Dept by
phone at +33 (0)4 78 26 40 46 or see the Company's Web site at:
http://www.edap-tms.com/ .
This press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties. These include
statements regarding the Company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission.
CONTACT:
EDAP TMS S.A.
Hugues de Bantel - Philippe Chauveau
Blandine Confort
+33 4 78 26 40 46
Halliburton Investor Relations
Matt Kreps - Geralyn DeBusk
972 458 8000
DATASOURCE: EDAP TMS S.A.
CONTACT: Hugues de Bantel, Philippe Chauveau or Blandine Confort, all of
EDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps or Geralyn DeBusk, both of
Halliburton Investor Relations, +1-972-458-8000, for EDAP TMS S.A.
Web site: http://www.edap-tms.com/